Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical development plan for monoclonal antibody H225 (a blocker of JAM-C, Junction Adhesion Molecule C).
top of page
Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization of monoclonal antibody H225 (a blocker of JAM-C, Junction Adhesion Molecule C). Under this program, executed in collaboration with the University Hospital of Geneva (HUG), the preclinical efficacy and safety profile of H225 were assessed in several animal models of B-cell lymphoma. The excellent results pave the way for further development of the product.
Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C)  as its lead preclinical development candidate for the treatment of drug-resistant B-cell lymphomas and potentially for the treatment of JAM-C (+) solid tumours.
bottom of page